RaDaR® ST

Studies in solid tumors across multiple cancer types have consistently demonstrated that detection of circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection after surgery or systemic therapy is associated with a markedly increased risk of disease relapse in the absence of additional treatment . Conversely, patients in whom ctDNA is not detected post-curative therapy exhibit a substantially lower risk of recurrence, reflecting minimal or absent residual disease burden and constitutes one of the strongest indicators of favorable prognosis in multi-cancer settings.

Additionally, across varied solid tumor cancer cohorts, longitudinal plasma analysis has shown that ctDNA detection can precede conventional imaging findings by several months, providing an early indicator of recurrence risk and enabling closer surveillance or therapeutic intervention. However, a negative ctDNA result does not definitively indicate the absence of cancer as not all recurrences shed sufficient ctDNA to be detected.

PMIDs: 27384348, 38614009, 40514443, 38409276, 40097663, 40973735, 35306155, 35658506, 35132238, 36732628, 40233104, 40846896, 40122951

RaDaR ST First Timepoint
Tissue:
A block is preferred for testing: 20 - 80% tumor content and >4 mm2 of tissue surface area for WES. If submitting 5-micron unstained slides, the following number of slides are requested: Samples with >25 mm2 of tissue: 10 unstained slides (2 sections per slide preferred) Samples with 10-24 mm2 of tissue: 20 unstained slides (2 sections per slide preferred) Please submit 1 additional unstained slide for H&E.

Peripheral Blood:
2 x 10 mL Streck Cell-Free DNA BCT® tubes

RaDaR ST Follow-up Timepoints
Peripheral Blood:
2 x 10 mL Streck Cell-Free DNA BCT® tubes

Use gel wrap for transport making sure gel wrap is not in direct contact with specimen. Do not refrigerate or freeze the gel wrap.
Tissue blocks and/or slides can be shipped at room temperature.
NYS clients: Please provide date and time of Collection.